Literature DB >> 2849123

Pharmacokinetics of WR-2721.

L M Shaw1, D Glover, A Turrisi, D Q Brown, H S Bonner, A L Norfleet, C Weiler, J H Glick, M M Kligerman.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2849123     DOI： 10.1016/0163-7258(88)90061-7

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  11 in total

Review 1.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis.

Authors:  A Keshavarzian; J Haydek; R Zabihi; M Doria; M D'Astice; J R Sorenson
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

Review 3.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

Review 4.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.

Authors:  M Treskes; U Holwerda; L G Nijtmans; H M Pinedo; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

7.  Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

Authors:  A E Korst; E Boven; M L van der Sterre; A M Fichtinger-Schepman; W J van der Vijgh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection.

Authors:  E J Lee; M Gerhold; M W Palmer; R D Christen
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

Review 9.  Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.

Authors:  Vijay K Singh; Patricia L P Romaine; Thomas M Seed
Journal:  Health Phys       Date:  2015-06       Impact factor: 1.316

10.  Amifostine protection against mitomycin-induced chromosomal breakage in fanconi anaemia lymphocytes.

Authors:  Ricardo M Camelo; Fernanda S G Kehdy; Carlos E Salas; Miriam T P Lopes
Journal:  Molecules       Date:  2008-08-21       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.